Microbix Biosystems Inc.
Microbix Biosystems Inc., a life science company, develops and commercializes proprietary biological and technological solutions for human health and wellbeing in North America, Europe, and internationally. The company manufactures a wide range of critical biological materials and medical devices for the global diagnostics industry, notably test ingredients (Antigen business) used in immunoassays… Read more
Market Cap & Net Worth: Microbix Biosystems Inc. (MBXBF)
Microbix Biosystems Inc. (OTCQX:MBXBF) has a market capitalization of $41.50 Million ($41.50 Million) as of March 18, 2026. Listed on the OTCQX stock exchange, this USA-based company holds position #24723 globally and #8502 in its home market, demonstrating a 4.91% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Microbix Biosystems Inc.'s stock price $0.30 by its total outstanding shares 138806329 (138.81 Million).
Microbix Biosystems Inc. Market Cap History: 2015 to 2025
Microbix Biosystems Inc.'s market capitalization history from 2015 to 2025. Data shows growth from $33.31 Million to $41.50 Million (1.49% CAGR).
Microbix Biosystems Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Microbix Biosystems Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.23x
Microbix Biosystems Inc.'s market cap is 2.23 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $24.60 Million | $9.52 Million | $748.41K | 2.58x | 32.87x |
| 2017 | $33.42 Million | $10.19 Million | -$3.78 Million | 3.28x | N/A |
| 2018 | $24.65 Million | $12.51 Million | -$8.62 Million | 1.97x | N/A |
| 2019 | $24.01 Million | $13.41 Million | $31.92K | 1.79x | 752.35x |
| 2020 | $45.81 Million | $10.52 Million | -$6.23 Million | 4.35x | N/A |
| 2021 | $91.20 Million | $18.59 Million | $3.23 Million | 4.90x | 28.20x |
| 2022 | $41.09 Million | $19.08 Million | $1.79 Million | 2.15x | 22.97x |
| 2023 | $39.00 Million | $16.51 Million | -$39.48K | 2.36x | N/A |
| 2024 | $30.82 Million | $25.39 Million | $3.52 Million | 1.21x | 8.75x |
| 2025 | $41.50 Million | $18.59 Million | -$2.25 Million | 2.23x | N/A |
Competitor Companies of MBXBF by Market Capitalization
Companies near Microbix Biosystems Inc. in the global market cap rankings as of March 18, 2026.
Key companies related to Microbix Biosystems Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Microbix Biosystems Inc. Historical Marketcap From 2015 to 2025
Between 2015 and today, Microbix Biosystems Inc.'s market cap moved from $33.31 Million to $ 41.50 Million, with a yearly change of 1.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $41.50 Million | +34.68% |
| 2024 | $30.82 Million | -21.00% |
| 2023 | $39.00 Million | -5.07% |
| 2022 | $41.09 Million | -54.95% |
| 2021 | $91.20 Million | +99.09% |
| 2020 | $45.81 Million | +90.75% |
| 2019 | $24.01 Million | -2.59% |
| 2018 | $24.65 Million | -26.25% |
| 2017 | $33.42 Million | +35.89% |
| 2016 | $24.60 Million | -26.17% |
| 2015 | $33.31 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Microbix Biosystems Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.50 Million USD |
| MoneyControl | $41.50 Million USD |
| MarketWatch | $41.50 Million USD |
| marketcap.company | $41.50 Million USD |
| Reuters | $41.50 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.